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Abstract 
Steroid receptor coactivator-3 (SRC-3), also known as AIB1, is a member of the p160 
steroid receptor coactivator family. Since SRC-3 was found to be amplified in breast 
cancer in 1997, the role of SRC-3 in cancer has been broadly investigated. SRC-3 initially 
was identified as a transcriptional coactivator for nuclear receptors such as the estrogen 
receptor (ER), involved in the proliferation of hormone-dependent cancers. However, 
increasing  clinical  evidence  shows  that  dysregulation  of  SRC-3  expression  in  several 
human hormone-independent cancers is correlated with pathological factors and clinical 
prognosis. Recently, both in vivo and in vitro studies demonstrate that SRC-3 may in-
fluence a number of cancer cellular processes in several ways independent of nuclear 
receptor signaling. In addition, an SRC-3 transgenic mice model shows that SRC-3 in-
duces tumors in several mouse tissues. These results indicate that the role of SRC-3 in 
cancer is not just as a nuclear receptor coactivator. The focus of this review is to examine 
possible SRC-3 roles in cancer, other than as a nuclear receptor coactivator. 
Key words: Steroid receptor coactivator-3; mice model; tumorigenesis; cell cycle; apoptosis; inva-
sion and metastasis 
Introduction 
Steroid  receptor  coactivator-3  (SRC-3)  is  a 
member of the p160 steroid receptor coactivator fam-
ily. It was discovered initially to be amplified in breast 
cancer in 1997 and so was named amplified in breast 
cancer 1 (AIB1)  (1). SRC-3 is also known as nuclear 
receptor coactivator-3 (NCoA-3), receptor associated 
coactivator-3  (RAC3),  activator  of  thyroid  hormone 
and  retinoid  receptor  (ACTR),  thyroid  hormone  re-
ceptor activating molecule-1 (TRAM1), and p300/CBP 
interacting protein (p/CIP). The SRC-3 gene is located 
on chromosome 20q12-12. The SRC-3 protein is ap-
proximately 160 kDa and contains three basic struc-
tural  domains,  consistent  with  the  other  two  SRC 
family members (SRC-1 and SRC-2). The N-terminal 
basic  helix-loop-helix-Per/ARNT/Sim  domain 
(bHLH-PAS) mediates the interaction between SRC-3 
and  other  DNA-binding  proteins.  The  recep-
tor-interaction  domain  (RID)  contains  three  LXXLL 
motifs, by which SRC-3 binds to the ligand-activated 
nuclear  receptors.  The  C-terminal  domain  contains 
two intrinsic transcriptional activation domains, AD1 
and  AD2,  by  which  SRC-3  interacts  with  histone 
acetyltransferases  and  histone  methyltransferases, 
respectively.  The  C-terminal  domain  of  SRC-3  also 
has histone acetyltransferase activity. The function of 
SRC-3  as  a  transcriptional  coactivator  for  nuclear 
hormone receptors has been described in detail pre-
viously  (2,  3).  Phosphorylated  SRC-3  binds  to  lig-
and-activated nuclear receptors via its RID, and then 
recruits  the  histone  acetyltransferase  p300/CBP 
through  AD1.  This  transcriptional  complex  subse-
quently alters chromatin structure and facilitates the 
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transcription of the nuclear receptor target gene. In 
addition to its role as a nuclear receptor coactivator, 
SRC-3  is also  a  transcriptional  coactivator  for  other 
transcription  factors,  including  E2F1  (4),  AP-1  (5), 
NF-κB (6), STAT6 (7) and PEA3 (8). Moreover, SRC-3 
acts  as  a  translational  repressor  to  regulate  proin-
flammatory cytokine mRNA translation (9). 
The correlation between SRC-3 and cancer has 
been widely discussed since SRC-3 was determined to 
be  amplified  in  breast  cancer  in  1997  (1).  Initially, 
SRC-3 was thought to be involved in the proliferation 
of  hormone-dependent  cancers,  such as  ER-positive 
breast cancer,  primarily by acting as transcriptional 
coactivator for nuclear receptors such as ER. Howev-
er,  more  and  more  studies  have  shown  that  hor-
mone-dependent  cancers  are  not  the  only  type  of 
cancer that SRC-3 affects, and SRC-3 has roles in can-
cer other than being as a nuclear receptor coactivator. 
Dysregulation  of  SRC-3  in  several  hor-
mone-independent cancers correlates with patholog-
ical factors and clinical prognosis. Both in vivo and in 
vitro studies show that SRC-3 affects many aspects of 
cancer in ways independent of nuclear receptor sig-
naling. The SRC-3 transgenic mice model shows that 
SRC-3 is a bona fide oncogene which can induce tu-
morigenesis in many tissues. The focus of this review 
is to summarize roles of SRC-3 in cancer other than a 
nuclear receptor coactivator.  
 
Clinical evidence of SRC-3 dysregulation in 
cancers 
The altered expression of SRC-3 in human can-
cers  is  summarized in  Table  1.  These  data  demon-
strate  that  dysregulation  of  SRC-3  occurs  in  hor-
mone-dependent  as  well  as  hormone-independent 
cancers. Moreover, SRC-3 dysregulation is correlated 
with  pathological  factors  and  prognosis  of  hor-
mone-dependent  as  well  as  hormone-independent 
cancers. These observations indicate that SRC-3 has a 
key role in the tumorigenesis and progression of sev-
eral  different  cancers,  and  not  just  a  coactivator  of 
nuclear hormone receptor. 
 
Table 1. SRC-3 dysregulation in cancers and malignant disease 
Changes   Frequency (Refs)  Pathological and Prognostic association (Refs) 
Hormone-dependent cancers 
Breast cancer 
Gene amplification  1.6-9.5% (1, 9-12)  Large tumor size (9) 
mRNA overexpression  13-64% (1, 13, 14)  High tumor grade (13) 
Shorter DFS and OS (14) 
Protein overexpression  16-53% (11, 15-19)  High tumor grade (16, 17), shorter DFS (18), shorter OS 
(18, 20), longer DFS (19) 
Prostate cancer 
Protein overexpression  13.1-37.9% (21, 22)  High tumor grade, stage and shorter DSS (21), PSA re-
currence (22) 
Ovarian cancer 
Gene amplification  7.4-25.8% (9, 23)  Shorter DFS (23) 
Protein overexpression  64% of the high grade tumors  (24)  High tumor grade (24) 
Endometrium cancer 
mRNA overexpression   17% (10)  High tumor grade and stage, shorter 24-months survival 
(25)  
Protein expression   93% (26)  High tumor grade (26)  
Hormone-independent cancers and malignant disease  
Esophageal squamous cell cancer (ESCC) 
Gene amplification  4.9-13% (27, 28)  ND 
Protein overexpression  46-64.3% (28, 29)  High tumor grade (28) 
Shorter PFS and DSS (29) 
Colorectal cancer 
Gene amplification  10-32% (30, 31)  ND 
Protein overexpression  35-56.5%  (30, 32)  High tumor grade (30)  
Longer OS  (32) 
Hepatocellular cancer (HCC) 
Gene amplification   41% of the metastatic HCC; 60% of the recur-
rent HCC (33) 
ND 
Protein overexpression  67.6% (34)  ND Int. J. Biol. Sci. 2011, 7 
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Pancreatic cancer 
Gene amplification  37% (35)  ND 
mRNA overexpression  73.68% (35)  ND 
Protein overexpression  64.47% (35)  ND 
Gastric cancer 
Gene amplification  41% (36) 
(7% high level amplification; 34% low level 
amplification) 
High regional lymph metastasis, high tumor grade and 
stage, poor prognosis  (36) 
mRNA overexpression  40% (36)  ND 
Bladder cancer 
Gene amplification  7.0% (37)  ND 
Protein overexpression  32.5% (37)  Shorter survival (37) 
Nasopharyngeal cancer 
Gene amplification  7% (38)  ND 
Protein overexpression  51% (38)  High lymph metastasis and tumor state (38)  
Non-small cell lung cancer (NSCLC) 
Gene amplification  8.2-25% (39, 40)  ND 
Protein overexpression  27-48.3% (39-41)  Shorter survival (39) 
Shorter DFS and OS (40) 
Meningioma 
Protein expression  76% (42)  ND 
DFS, disease free survival; OS, overall survival; DSS, disease specific survival; PFS, progression free survival; PSA, prostatic specific antigen; 
ND, not determined; HCC, hepatocellular cancer; ESCC, esophageal squamous cell cancer; NSCLC, non-small cell lung cancer. 
 
Mouse model reveals the oncogenic prop-
erty of SRC-3 
SRC-3 knockout mice model 
To analyze the relationship between SRC-3 and 
cancer, researchers generated several mouse models 
of  cancers  in  which  SRC-3  is  depleted.  The  results 
showed  that  SRC-3  knockout  significantly  inhibited 
carcinogen-induced  tumorigenesis  by  inducing 
down-regulation of other signaling pathways, as well 
as  nuclear  receptor  signaling.  For  example,  in  two 
different mouse  models, SRC-3  knockout totally in-
hibited  the  mouse  mammary  tumor  virus-v-Ha-ras 
(MMTV-v-Ha-ras)  or  chemical  carcinogen  7, 
12-dimethyl-benz[a]  anthracene  (DMBA)-mediated 
mammary  gland  tumorigenesis  (44,  45).  The 
down-regulation  of  the  IGF-I  signaling  detected  in 
both of these models is considered one reason, as is 
the  down-regulation  of  ER  signaling.  Moreover, 
SRC-3 depletion led to the inhibition of the oncogene 
MMTV-HER2/neu induced mammary gland tumor-
igenesis  in  another  mouse  model,  in  which  HER-2 
phosphorylation was suppressed (46). More recently, 
it was reported that SRC-3 knockout also prevented 
the  initiation  of  thyroid  cancer  induced  by  domi-
nant-negative  mutant  thyroid  hormone  receptor-β 
(TR-β), and multiple signaling pathways, but not nu-
clear receptor signaling, were disrupted in this mouse 
model (47).Taken together, these results indicate that 
SRC-3  contributes  to  the  tumorigenesis  induced  by 
several different carcinogens. 
SRC-3 transgenic mice model 
To detect whether SRC-3 overexpression could 
induce  tumorigenesis  in  the  mammary  gland, 
Torres-Arzayus  and  colleagues  (48)  established  the 
first SRC-3 transgenic mouse model in 2004. In this 
model, tumors were induced in the mammary gland 
(48%).  Surprisingly,  tumors  were  also  found  in  the 
pituitary (42%), uterus (18%) and lung (18%). More-
over,  16.7%  of  the  mammary  gland  tumors  were 
ERα-negative. Further studies revealed that activation 
of  IGF-I  signaling  was  enhanced  in  this  SRC-3-tg 
mouse model, indicating that SRC-3 induced tumor-
igenesis  by  up-regulating  IGF-I  signaling.  More  re-
cently,  the same  group  developed another  estrogen 
receptor  signaling-eliminated  SRC-3  transgenic 
mouse model by two methods, ovariectomy (ovx) and 
ERα null mutant  (49). In both groups, ectopic SRC-3 
overexpression  still  induced  tumorigenesis  in  lung, 
pituitary, skin, and bone tissues. Meanwhile, in the 
ovx group, although the ovariectomy attenuated es-
trogen  receptor  signaling  and  inhibited  mammary 
gland  development,  some  mice  still  developed 
mammary hyperplasia and ductal carcinoma. Taken 
together, the data from these two SRC-3  transgenic 
mouse models strongly indicate that SRC-3 triggers 
tumorigenesis through either other nuclear receptor 
signals or in a nuclear receptor signaling-independent 
manner,  although  the  details  of  the  mechanism  are 
not fully understood. Int. J. Biol. Sci. 2011, 7 
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SRC-3 is involved in cancers in a nuclear receptor 
signaling-independent manner  
Several  investigations  indicated  that  SRC-3  is 
implicated in cancer through nuclear receptor signal-
ing-independent  as  well  as  nuclear  receptor  signal-
ing-dependent mechanisms. Here, we intend to focus 
on the role of SRC-3 in cancer other than as a nuclear 
receptor coactivator (Figure 1). 
 
 
 
 
Figure 1. SRC-3 is involved in many cancer processes independent of nuclear receptor signaling. SRC-3 promotes cell 
cycle progression by coactivating E2F1 and activating Akt. SRC-3 up-regulates IGF-I and EGF signaling by phosphor-
ylating Akt, EGFR and HER2, respectively, and induces tumorigenesis. SRC-3 inhibits apoptosis through activation of 
NF-ΚB and Akt signaling. SRC-3 promotes invasion and metastasis by coactivating AP-1 and PEA3 and activating FAK. 
 
 
 
SRC-3 is involved in cell cycle control 
Cancer is considered to be a disease of the cell 
cycle, and compromised cell cycle control is detected 
frequently in several cancers  (50). There is evidence 
that  SRC-3  may  promote  the  cancer  cell  cycle.  For 
example,  SRC-3  overexpression  maintained  the  S 
phase cell number in fulvestrant-treated breast cancer 
cell  line  T47D  (4).  In  contrast,  the  SRC-3  stable 
knockdown by siRNA decreased S phase cell number 
and increased G1 phase cell number both in human 
embryonic lung fibroblast and HCC cell lines (35, 51). 
Moreover, SRC-3 depletion induced a significant in-
crease in G1/G0 phase cells and a decrease in G2/M 
phase  cells  in  TR-β-induced  thyroid  cancer  mouse 
model  (47).  Another  proof  was  that  SRC-3  nuclear 
translocation  was  coincident  with  the  G1/S  phase 
transition of cancer cell (51, 52). 
Other  research  examined  the  mechanism  by 
which  SRC-3  modulates  cell  cycle  control  in  cancer 
cells.  One group  found  that  SRC-3  acted  as a  tran-
scriptional  coactivator  for  the  G1/S  phase  transi-
tion-associated transcription factor E2F1, and enhance 
the transcription of the E2F1 target genes, which are 
mostly G1/S cycle transition-related proteins  (4,  51). 
Therefore, SRC-3 dysregulation eventually led to cell 
cycle activation through E2F1 signaling. This conclu-
sion is supported by the fact that SRC-3 overexpres-
sion induced proliferation and transformation of the 
ER-negative  human  mammary  epithelial  cell  line 
MCF10A  in  an  E2F1-dependent  manner  (51).  Inter-
estingly, other studies show that SRC-3 may promote 
its own transcription with E2F1 (53, 54). This positive 
feedback regulatory loop may enhance the influence 
SRC-3 exerted on cell cycle control. In addition, SRC-3 
also influenced cell cycle control through activation of Int. J. Biol. Sci. 2011, 7 
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the  Akt  signaling  pathway.  For  example,  SRC-3  in-
hibited cell cycle inhibitor p21Cip1/Waf1 expression by 
activating Akt signaling in HCC cells  (35). Taken to-
gether, these data demonstrate that SRC-3 is involved 
in cell cycle control-related signaling. The dysregula-
tion of SRC-3 may disturb normal cell cycle progres-
sion and promote cancer initiation and proliferation. 
SRC-3 and growth factor signaling 
SRC-3 regulates the insulin-like growth factor I 
(IGF-I) signaling  
IGF-I  signaling  is  involved  in  many  important 
cell  processes  related  to  cancer  (55).  Many  studies 
showed that SRC-3 is associated with the regulation of 
IGF-I  signaling  in  cancer.  In  vivo,  SRC-3  knockout 
down-regulated IGF-I mRNA and protein expression, 
and thus inhibited tumorigenesis (44, 56, 57). In con-
trast,  ectopic  SRC-3  overexpression  up-regulated 
IGF-I  mRNA  and  protein  expression  and  induced 
tumorigenesis  in  a  mouse  model  (48).  Moreover, 
SRC-3  expression  also  influenced  the  expression  of 
many IGF-I signaling components, such as IGF-I re-
ceptor β (IGF-IRβ)  (45), IRS-1 and IRS-2  (44,  45). In 
accordance  with  in vivo  studies,  the  in vitro studies 
also demonstrated that SRC-3 could regulate the ex-
pression  of  IGF-I  signaling  components  (58,  59).  In 
addition,  SRC-3  modulated  the  activation  of  IGF-I 
signaling components in vitro and in vivo. For exam-
ple, SRC-3 overexpression enhanced Akt phosphory-
lation  in  two  prostate  cancer  cell  lines,  PC3  and 
LNCaP (58). The cancer cells derived from the SRC-3 
transgenic mice showed excessive activation of com-
ponents of the IGF-I/PI3K/Akt/mTOR pathway, in 
particular Akt  (48). Both in vivo and in vitro studies 
indicate  that  SRC-3  is  tightly  correlated  with  IGF-I 
signaling in cancers. 
Quite a few studies have been performed on the 
mechanism of SRC-3 regulating the IGF-I signaling in 
cancers.  SRC-3  can  bind  to  the  transcription  factor 
AP-1  and  enhance  AP-1-mediated  transcription  of 
IGF-I and IRS-1  (5). IGF-binding protein 3 (IGFBP3) 
inhibited the degradation of serum IGF-I by forming a 
complex with IGF-I (60). A recent study showed that 
SRC-3 could affect the IGF protein level through reg-
ulation of IGFBP3 expression (61). In this study, mu-
tation of the phosphorylation sites of SRC-3 increased 
IGF-I  expression  by  up-regulating  IGFBP3,  and  re-
sulted in tumorigenesis in the mouse liver. These re-
sults can account partly for the association between 
SRC-3 and IGF-I signaling. However, the mechanism 
by which SRC-3 modulates the expression and acti-
vation  of  IGF-I  signaling  components,  in  particular 
the activation of Akt, needs further exploration. Col-
lectively, the above results indicate that dysregulation 
of SRC-3 influences the expression and activation of 
IGF-I signaling components.  
SRC-3 regulates EGF signaling 
EGF signaling is important for the initiation and 
progression  of  cancer  (62).  Clinical  studies  showed 
that SRC-3 overexpression correlated with expression 
of the EGFR family member HER2 in breast cancer 
specimens, and the expression of both of these pro-
teins  correlated  with  shorter  survival  and  primary 
tamoxifen resistance in breast cancer patients (13, 20). 
A recent in vitro study showed that endogenous SRC-3 
knockdown by siRNA in lung, pancreatic and breast 
cancer cell lines reduced EGF-mediated phosphoryla-
tion of EGFR and HER-2, and thereby inhibited the 
activation of EGF signaling  (63). As a result, cancer 
cell  proliferation  was  inhibited.  An  in  vivo  study 
showed  that  SRC-3  depletion  completely  inhibited 
mammary  tumorigenesis  induced  by  the  oncogene 
MMTV-HER2/neu (46). Further studies revealed that 
SRC-3  depletion  strongly  prevented  HER-2  phos-
phorylation  and  thus  inhibited  the  HER2-induced 
activation of EGF/MAPK signaling. Although neither 
of these studies thoroughly elucidated the mechanism 
by which SRC-3 regulate EGFR and HER2 phosphor-
ylation, they still confirm that SRC-3 regulates EGF 
signaling.  
SRC-3 and apoptosis 
Apoptosis is a normal physiological process of 
the cell; altered regulation of apoptosis is common in 
cancer  (64). Many studies showed that SRC-3 is im-
plicated in the cancer cell apoptosis. In vitro, overex-
pression of SRC-3 reduced H2O2-mediated apoptosis 
in  the  HEK293  cell  line  (65).  In  contrast,  SRC-3 
down-regulation by siRNA restored the sensitivity of 
chronic myeloid leukemia cell line K562 to tumor ne-
crosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL)-mediated apoptosis  (66), decreased apopto-
sis  inhibitor  Bcl-2  expression  in  the  prostate  cancer 
cell line PC3  (23), and increased the level of cleaved 
caspase-7  in  the  NSCLC  cell  line  H1299  (23,  41). 
Moreover,  in  vivo  studies  also  showed  that  SRC-3 
possessed anti-apoptotic properties (47, 48).  
NF-κB signaling inhibits apoptosis by regulating 
the  transcription  of  many  anti-apoptotic  proteins, 
such as Bcl-2 and the FLICE inhibitory protein (FLIP) 
(67, 68). SRC-3 activated NF-κB signaling in coordina-
tion with IκB kinase (IKK) and acted as a transcrip-
tional  coactivator  for  NF-κB  in  cancer  cells  (6,  69). 
Therefore,  researchers  examined  whether  SRC-3  af-
fected  apoptosis  through  NF-κB  signaling.  SRC-3 
knockdown by siRNA indeed reduced activation of Int. J. Biol. Sci. 2011, 7 
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NF-κB signaling and resulted in apoptosis in human 
chronic myeloid leukemia K562 cells  (66), while an-
other study showed that SRC-3 overexpression acti-
vated NF-κB-mediated anti-apoptosis gene transcrip-
tion  in  HEK293  cells  (65).  More  recently,  another 
study  showed  that  SRC-3  down-regulation  induced 
by deguelin in Jurkat cells inhibited the expression of 
NF-κB target genes known to be anti-apoptotic  (70). 
All of these results demonstrate that SRC-3 may de-
crease  apoptosis  by  activating  NF-κB  signaling  in 
cancer cells. In addition, SRC-3 also disturbed apop-
tosis  through  Akt  signaling,  which  is  involved  in 
multiple apoptosis signaling pathways (71-73). An in 
vitro study showed that SRC-3 knockout reduced Akt 
activation,  and  thus  attenuated  Akt-mediated  JNK 
suppression, resulting in apoptosis of DT40 chicken 
B-lymphocytes  (74). Another study revealed that in-
hibiting  SRC-3  expression  by  gambogic  acid  in  the 
human leukemia cell line K562 also inactivated Akt 
signaling, thereby decreasing Bcl-2 expression (75). In 
contrast, SRC-3 overexpression in HEK293 cells pre-
vented apoptosis in part by activating Akt signaling 
(65). These data demonstrate that SRC-3 suppression 
of apoptosis in several cancer cells is through activa-
tion of NF-κB and Akt signaling. 
SRC-3 promotes invasion and metastasis  
Invasion  and  metastasis  play  critical  roles  in 
cancer progression (76). Several studies indicated that 
SRC-3  promoted  cancer  invasion  and  metastasis. 
Clinically, SRC-3 overexpression was associated with 
local invasion (25, 26, 34, 77) and lymph node metas-
tasis  (30,  37,  39,  77). In vitro, SRC-3 modulated cell 
invasion and migration in a nuclear receptor signal-
ing-independent manner  (25,  77,  78). In an SRC-3-tg 
mouse model, most cancers induced by ectopic SRC-3 
overexpression were invasive and metastatic (48, 49). 
In contrast, the SRC-3 knockout mouse model showed 
that loss of SRC-3 inhibited cancer invasion and me-
tastasis (8, 44, 47, 79). 
There have been many studies on the mechanism 
by  which  SRC-3  regulates  cancer  invasion  and  me-
tastasis. Some studies focused on the correlation be-
tween SRC-3 and matrix metalloproteinases (MMPs). 
One study found that SRC-3 stimulated MMP7 and 
MMP10  expression  in  ER-negative  MDA-MB-231 
breast cancer cells by acting as coactivator for tran-
scription factor AP-1  (78). Another study found that 
SRC-3  promoted  MMP2  and  MMP13  expression  in 
LNCaP prostate cancer cells by coactivating PEA3, an 
Ets  transcription  factor  family  member,  as  well  as 
AP-1 (77). In accordance with the in vitro studies, an in 
vivo  study  also  demonstrated  that  SRC-3  enhanced 
MMP2  and  MMP9  expression  by  functioning  as  a 
transcriptional coactivator for PEA3 (8). In addition to 
regulating the expression of MMPs, SRC-3 also was 
shown  to  activate  focal  adhesion  kinase  (FAK)  sig-
naling, and thus enhance cell motility, which is critical 
to  the  cancer  invasion  and  metastasis.  A  study 
showed that SRC-3 promoted FAK phosphorylation 
and thus induced tumor cell migration (77). More re-
cently, another study showed that SRC-3Δ4, a nuclear 
localization  signal  (NLS)-deleted  isoform  of  SRC-3, 
could  function  as  an  adaptor  protein  for  signal 
transmission from EGFR to FAK (80). Taken together, 
the above studies demonstrated that SRC-3 promotes 
cancer invasion and metastasis by mechanisms other 
than nuclear receptor signaling.  
Conclusion 
Accumulating evidence indicates that the role of 
SRC-3 in cancer is more than as a  nuclear  receptor 
coactivator. Clinical investigations showed that SRC-3 
is not only associated with hormone-dependent can-
cers.  In  the  SRC-3-tg  mouse  model,  SRC-3  ectopic 
overexpression induced tumorigenesis in several or-
gans, even when a prototypical nuclear hormone re-
ceptor  signaling  is  eliminated.  In  contrast,  SRC-3 
knockout in mice inhibited tumorigenesis induced by 
multiple  different  carcinogens.  Both  in vitro  and  in 
vivo studies demonstrated that SRC-3 is involved in 
many cancer processes through several mechanisms, 
in  particular  the  nuclear  receptor-independent  sig-
naling.  SRC-3  controlled  cell  cycle  progression  by 
coactivating  E2F1,  up-regulated  IGF-I  and  EGF  sig-
naling,  inhibited  apoptosis  through  activation  of 
NF-κB and Akt signaling and promoted invasion and 
metastasis by coactivating AP-1 and PEA3 and acti-
vating FAK.  
A  recent  study  showed  that  SRC-3  deficiency 
reduced apoptosis by up-regulating NF-κB signaling 
in T and B lymphocytes, and eventually lead to lym-
phoma  (81). This indicated that the mechanisms in-
dependent  of  nuclear  receptor  signaling  by  which 
SRC-3 is involved in cancers is complex and requires 
further investigation in the future. All of the above 
data demonstrate that SRC-3 has roles in cancer initi-
ation and progression other than being as a nuclear 
receptor coactivator. Therefore, SRC-3 may be an at-
tractive target of cancer therapy. 
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